Technical Analysis for CYCCP - Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

Grade Last Price % Change Price Change
grade F 5.48 -21.60% -1.51
CYCCP closed down 21.6 percent on Monday, June 1, 2020, on 74 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical CYCCP trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Narrow Range Bar Range Contraction -21.60%
Upper Bollinger Band Walk Strength -21.60%
Wide Bands Range Expansion -21.60%
Gapped Down Weakness -21.60%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases. The company's oncology development programs include its lead candidate, sapacitabine, which is in Phase III study that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and second drug candidate, seliciclib, which is an orally-available CDK inhibitor that selectively inhibits a spectrum of enzyme targets, including CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its oncology development programs also comprise Plk1 Inhibitors, which is in preclinical stage for the treatment of cancer; CYC065, an orally-available 2nd generation inhibitor of CDK-2, -5, and -9 that helps in cancer cell growth, metastatic spread, and DNA damage repair; and Sapacitabine + Seliciclib, which is in Phase I trial for the treatment of cancer. The company's non-oncology programs include Cell Cycle Inhibitors, which completed Phase I trial for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Biopharmaceutical Cancer Biology Treatment Of Cancer Cell Biology Serious Diseases Autoimmune And Inflammatory Diseases Cyclacel Treatment Of Autoimmune And Inflammatory Diseases Dna Synthesis PLK1 Cdk Inhibitor Cell Cycle Cell Cycle Checkpoint Cyclin Dependent Kinase Cyclin Dependent Kinase 2 E Human Cancers M Checkpoint Sapacitabine Seliciclib

Is CYCCP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.75
52 Week Low 3.87
Average Volume 678
200-Day Moving Average 5.70
50-Day Moving Average 5.97
20-Day Moving Average 6.38
10-Day Moving Average 6.63
Average True Range 0.61
ADX 17.18
+DI 31.05
-DI 39.78
Chandelier Exit (Long, 3 ATRs ) 6.23
Chandelier Exit (Short, 3 ATRs ) 7.04
Upper Bollinger Band 7.58
Lower Bollinger Band 5.18
Percent B (%b) 0.13
BandWidth 37.65
MACD Line 0.23
MACD Signal Line 0.24
MACD Histogram -0.0133
Fundamentals Value
Market Cap 62.47 Million
Num Shares 11.4 Million
EPS -2.37
Price-to-Earnings (P/E) Ratio -2.32
Price-to-Sales 165.09
Price-to-Book 2.66
PEG Ratio 0.00
Dividend 0.60
Dividend Yield 10.95%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.70
Resistance 3 (R3) 6.83 6.56 6.49
Resistance 2 (R2) 6.56 6.25 6.49 6.42
Resistance 1 (R1) 6.02 6.06 5.89 5.89 6.36
Pivot Point 5.75 5.75 5.68 5.68 5.75
Support 1 (S1) 5.21 5.44 5.08 5.08 4.60
Support 2 (S2) 4.94 5.25 4.87 4.54
Support 3 (S3) 4.40 4.94 4.47
Support 4 (S4) 4.27